Benzinga | Oct 1, 2021 07:13AM EDT

Ascendiant Capital Initiates Coverage On Alzamend Neuro with Buy Rating, Announces Price Target of $8

Ascendiant Capital analyst Edward Woo initiates coverage on Alzamend Neuro (NASDAQ:ALZN) with a Buy rating and announces Price Target of $8.